News
MinervaX begins critical GBS vaccine trial
MinervaX – a biotechnology concentrating on a group B streptococcus (GBS) vaccine – has announced the first phase 1 clinical study among older adults. The research will unfold at the CEVAC (Centre for Vaccinology) in Belgium.